Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | CNOT7 | Q9UIV1 | 5/20 | 0.40 |
| ▸ | PARN | O95453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8481075 | 1.00 | PDE4A (0.45) | PDE4ALMNAESR1CYP1A2MAPT | |
| SCHEMBL8484574 | 0.94 | PDE4A (0.48) | PDE4ALMNAESR1CYP1A2MAPT | |
| SCHEMBL8480234 | 0.88 | PDE4A (0.51) | PDE4ALMNAESR1CYP1A2MAPT | |
| Fumaric Acid SCHEMBL8485980 | 0.86 | PDE4A (0.50) | PDE4ALMNAESR1CYP1A2MAPT | |
| Fumaric Acid SCHEMBL8485971 | 0.86 | PDE4A (0.50) | PDE4ALMNAESR1CYP1A2MAPT | |
| SCHEMBL8483332 | 0.85 | PDE4A (0.46) | PDE4ALMNAESR1CYP1A2MAPT | |
| SCHEMBL8481081 | 0.85 | PDE4A (0.45) | PDE4ALMNAESR1CYP1A2MAPT | |
| SCHEMBL8484589 | 0.85 | PDE4A (0.45) | PDE4ALMNAESR1CYP1A2MAPT | |
| Fumaric Acid SCHEMBL8479267 | 0.83 | PDE4A (0.43) | PDE4ALMNAESR1CYP1A2MAPT | |
| Fumaric Acid SCHEMBL8479274 | 0.83 | PDE4A (0.43) | PDE4ALMNAESR1CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5965555-A | TREATMENT AND/OR PROPHYLAXIS OF CEREBROVASCULAR DISORDERS CHARACTERIZED BY DAMAGE CAUSED BY ISCHEMIA AND SUBSEQUENT NECROTIC DESTRUCTION OF NERVE CELLS(NEURONS) | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |